A carregar...
Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
BACKGROUND: The aim of our study was to retrospectively assess the incidence of interstitial lung disease (ILD) related to EGFR‐tyrosine kinase inhibitor (TKI) treatment immediately before and/or after the administration of a PD‐1 antibody. METHODS: We analyzed the data of 26 patients who underwent...
Na minha lista:
| Publicado no: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons Australia, Ltd
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6449223/ https://ncbi.nlm.nih.gov/pubmed/30864291 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13039 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|